CABA - CIK 0001759138
The table below shows Cabaletta Bio, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$131.08M | -$88.22M | -$53.55M | -$46.38M | -$34.11M | -$26.77M |
| Capital expenditure | $1.23M | $2.21M | $687.00K | $2.45M | $1.17M | $635.00K |
| Investing cash flow | -$50.27M | $47.29M | -$22.45M | -$27.22M | $6.00M | -$7.98M |
| Dividends paid | - | - | - | - | - |
Cabaletta Bio, Inc. reported operating cash flow of -$131.08M for fiscal year 2025. That is down 48.6% from -$88.22M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$4.66M (FY 2018) to -$131.08M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $100.35M | $11.68M | $187.63M | $32.98M | $48.90M | -$24.00K |